P-Glycoprotein Inhibitors

Janus Kinase Inhibitors

Janus Kinase Inhibitor

Dermatitis, Atopic

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>CIBINQO (abrocitinib) tablets contain the free base of abrocitinib, a Janus kinase (JAK) inhibitor, for oral administration.Abrocitinib is a white to pale colored powder with the following chemical name: N-((1s,3s)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamideThe solubility of abrocitinib in water is 0.04 mg/mL at 25ºC.Abrocitinib has a molecular weight of 323.42 g/mol and a molecular formula of C14H21N5O2S. The structural formula of abrocitinib is:<div class="Figure"><a name="id1860"></a><img alt="Chemical Structure" src="cibinqo-01.jpg"/></div>Each film-coated tablet contains 50 mg or 100 mg or 200 mg of abrocitinib and the following inactive ingredients: dibasic calcium phosphate anhydrous, hypromellose, iron oxide red, lactose monohydrate, Macrogol, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, titanium dioxide, and triacetin.</section>

CIBINQO

abrocitinib

abrocitinib 100 MG Oral Tablet

Cibinqo

abrocitinib 100 MG Oral Tablet [Cibinqo]

abrocitinib 200 MG Oral Tablet

abrocitinib 200 MG Oral Tablet [Cibinqo]

abrocitinib 50 MG Oral Tablet

abrocitinib 50 MG Oral Tablet [Cibinqo]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Cibinqo (abrocitinib) is a medication in the form of an oral tablet. It is used to treat moderate to severe eczema in adults who are unable to use topical medications or whose eczema has not responded to topical medications. Eczema is a skin condition characterized by dry and itchy skin that can result in red and scaly rashes.

Cibinqo is FDA approved for the following indications: atopic dermatitis

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Online Sample Form

Coverage Authorization Request 

Coverage Authorization Appeal 

Letter of Medical Necessity 

Pfizer Dermatology Patient Access HCP Portal Enrollment Form 

Pfizer Dermatology Patient Access Enrollment Form 

Pfizer Dermatology Patient Access - HCP Portal 

Enroll in Patient Savings Program 

Download Co-Pay Card: HCP Office Only

Patient Assistance Program Enrollment Form 

Bridge Program 

Other HCP Resources 

Cibinqo Support 

About Cibinqo

Before and After 

Taking Cibinqo

Side Effects 

Doctor Discussion Guide 

Instructions For Use: Atopic Dermatitis (Eczema)

Starting and Monitoring Cibinqo

Downloadable Patient Education Materials